Claudia Tulotta
Overview
Explore the profile of Claudia Tulotta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Van Avondt K, Strecker J, Tulotta C, Minnerup J, Schulz C, Soehnlein O
Immunol Rev
. 2022 Oct;
314(1):357-375.
PMID: 36315403
Over the past millennia, life expectancy has drastically increased. While a mere 25 years during Bronze and Iron ages, life expectancy in many European countries and in Japan is currently...
3.
Zhou J, Down J, George C, Murphy J, Lefley D, Tulotta C, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230739
Breast cancer bone metastasis is currently incurable. Evidence suggests that inhibiting IL-1 signalling with the IL1R antagonist, Anakinra, or the IL1β antibody, Canakinumab, prevents metastasis and almost eliminates breast cancer...
4.
Zhou J, Tulotta C, Ottewell P
Expert Rev Mol Med
. 2022 Mar;
24:e11.
PMID: 35227338
Bone is the most common site for advanced breast cancer to metastasise. The proinflammatory cytokine, interleukin-1β (IL-1β) plays a complex and contradictory role in this process. Recent studies have demonstrated...
5.
Tulotta C, Lefley D, Moore C, Amariutei A, Spicer-Hadlington A, Quayle L, et al.
NPJ Breast Cancer
. 2021 Jul;
7(1):95.
PMID: 34290237
Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in bone and available treatments are only palliative. We have previously shown that...
6.
Berning P, Hennemann C, Tulotta C, Schaefer C, Lechtape B, Hotfilder M, et al.
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32272784
The receptor tyrosine kinase (RTK) RON is linked to an aggressive metastatic phenotype of carcinomas. While gaining interest as a therapeutic target, RON remains unstudied in sarcomas. In Ewing sarcoma,...
7.
Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, et al.
Breast Cancer Res
. 2019 Dec;
21(1):130.
PMID: 31783893
Background: Late-stage breast cancer preferentially metastasises to bone; despite advances in targeted therapies, this condition remains incurable. The lack of clinically relevant models for studying breast cancer metastasis to a...
8.
Eyre R, Alferez D, Santiago-Gomez A, Spence K, McConnell J, Hart C, et al.
Nat Commun
. 2019 Nov;
10(1):5016.
PMID: 31676788
Dissemination of tumour cells to the bone marrow is an early event in breast cancer, however cells may lie dormant for many years before bone metastases develop. Treatment for bone...
9.
Rahman A, Henry K, Herman K, Thompson A, Isles H, Tulotta C, et al.
Elife
. 2019 Oct;
8.
PMID: 31613219
Neutrophilic inflammation with prolonged neutrophil survival is common to many inflammatory conditions, including chronic obstructive pulmonary disease (COPD). There are few specific therapies that reverse neutrophilic inflammation, but uncovering mechanisms...
10.
Tulotta C, Groenewoud A, Snaar-Jagalska B, Ottewell P
Methods Mol Biol
. 2019 Feb;
1914:309-330.
PMID: 30729473
This chapter is designed to provide a comprehensive overview outlining the different in vivo models available for research into breast cancer bone metastasis. The main focus is to guide the...